

ABIVAX

\$236 Million

U.S. Initial Public Offering

LEERINK 
PARTNERS

Joint Global
Coordinator and Bookrunner
October 2023

Leerink Partners Serves as Joint Global Coordinator and Bookrunner for Abivax's (Nasdaq: ABVX) \$236 Million U.S. Initial Public Offering

Key Transaction Highlights

- Abivax is a French publicly traded company on the Euronext Paris and after successfully pricing its U.S. initial public offering, will now also trade on the Nasdaq Global Market under the ticker ABVX.
- Priced on October 19, 2023 at \$11.60 per ADS and €10.9864 per ordinary share
- Well oversubscribed from both new and existing investors
- Deal consisted of 18,699,460 ADSs and 1,626,040 ordinary shares for gross total proceeds of \$235.8 million
- Abivax intends to use the net proceeds from this offering to fund the development of obefazimod for UC, CD, and the remainder for working capital and for other general corporate purposes.
- This transaction represents Leerink Partners' 2nd equity offering for Abivax, 3rd bookrun IPO, and 45th equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111